ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer

Fu, Yongming; Cao, Tuoyu; Zou, Xiaorui; Ye, Yubing; Liu, Youhong; Peng, Yuchong; Deng, Tanggang; Yin, Linglong; Li, Xiong*广东药学院; 1
Oncogenesis2023-1-2DOI: 10.1038/s41389-022-00446-y
4被引6阅读
引用收藏
分享

摘要

Oncogenic activation of PI3K/AKT signaling pathway, together with epigenetic aberrations are the characters of castration-resistant prostate cancer (CRPC). UHRF1 as a key epigenetic regulator, plays a critical role in prostate cancer (PCa) development, and its expression is positively correlated with the degree of malignancy. In this present study we investigated the potential regulatory mechanism of AKT1 on UHRF1, and further validated the in vitro and in vivo anticancer efficacy of AKT phosphorylation inhibitor MK2206 in combination with abiraterone. Both UHRF1 and p-AKT aberrantly overexpressed in the abiraterone-resistant PCa cells. Further studies revealed that AKT1 protein interacts with UHRF1, and AKT1 directly phosphorylates UHRF1 via the site Thr-210. MK2206 induced UHRF1 protein degradation by inhibiting AKT1-induced UHRF1 phosphorylation, and then reduced the interaction between UHRF1 and deubiquitinase USP7, while promoted the interaction between UHRF1 and E3 ubiquitin protein ligase BTRC. MK2206 significantly promoted the sensitivity of abiraterone-refractory PCa cells and xenografts to abiraterone by decreasing UHRF1 protein level, and reversed the phenotype of NEPC, evently induced cellular senescence and cell apoptosis. Altogether, our present study for the first time revealed a novel molecular mechanism of abiraterone resistance through PI3K/AKT-UHRF1 pathway, and provided a novel therapeutic modality by targeting PI3K/AKT1 to promote the drug sensitivity of abiraterone in PCa patients.

学科与关键词

关键词
INCREASED SURVIVALDNA METHYLATIONPHOSPHORYLATIONREPLICATIONMETASTASISMECHANISMSMARKER
相关
加载中…
  • Diosgenin inhibits prostate cancer progression by inducing UHRF1 protein degradation
    Peng, Yuchong; Tang, Rong; Ding, Liuyang; Zheng, Rirong; Liu, Youhong; Yin, Linglong; Fu, Yongming; Deng, Tanggang; Li, Xiong*European Journal of Pharmacology, 2023, 942: 175522.被引 4
  • A novel small-molecule activator of unfolded protein response suppresses castration-resistant prostate cancer growth
    Chen, Huang; Miao, Ying; Bian, Aiwu; Ye, Jiangnan; Wang, Jing; Cong, Xiaonan; Jian, Shuyi; Yi, Zhengfang; Liang, Lin; Sun, Zhenliang*; Yang, Fan*; Ding, Tao*Cancer Letters, 2022, 532: 215580.被引 5
  • Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancer
    Li, Jianhua; Wu, Huanxian; Lv, Shidong; Quan, Dongling; Yang, Danni; Xu, Jiahuan; Chen, Boyu; Ou, Baofang; Wu, Shaoyu*; Wei, Qiang*Die Pharmazie, 2022, 77(2): 59-66.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Oncogenesis
发表日期
2023-01-02
卷期
第 12 卷, 第 1 期
页码
1
DOI
10.1038/s41389-022-00446-y
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China; National Key Specialty Construction Project of Clinical Pharmacy, High Level Clinical Key Specialty of Clinical Pharmacy in Guangdong Province [NSFC 81572542, NSFC 81874096]; Research Project of Key Discipline of Guangdong Province; Science and Technology Program of Guangzhou City [2019GDXK0010]; [202102021130]

作者

  • F

    Fu, Yongming (第一作者)

    1 · guangdong pharmaceut univ

  • C

    Cao, Tuoyu

查看全部 9 位作者收起作者
  • Z

    Zou, Xiaorui

    guangdong pharmaceut univ

  • Y

    Ye, Yubing

    guangdong pharmaceut univ

  • L

    Liu, Youhong

  • P

    Peng, Yuchong

    1 · guangdong pharmaceut univ

  • D

    Deng, Tanggang

    1 · guangdong pharmaceut univ

  • Y

    Yin, Linglong

    1 · guangdong pharmaceut univ

  • L

    Li, Xiong (通讯)

    1 · guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417